N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT01265563
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 108 participants
- Sponsor
- Registry
-
NCT01265563
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01265563. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2017-03-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
- Acronym
- CGDN
- Condition
- Diabetic Nephropathy
- Condition
- Proteinuria
- Condition
- Oxidative Stress
- Intervention (Drug)
- N-acetylcysteine placebo and silibin placebo
- Intervention (Drug)
- N-acetylcysteine active and silibin placebo
- Intervention (Drug)
- N-acetylcysteine placebo and silibin active
- Intervention (Drug)
- N-acetylcysteine active and silibin active
- Intervention (Drug)
- N-acetylcysteine active + high-dose silibin active
- Lead sponsor
- VA Office of Research and Development
- Collaborator
- National Center for Complementary and Integrative Health (NCCIH)
Record details
- Record id
cardio:ct-nct01265563- Content hash
cedd7f98fc97b1851c8829538db7b3da7c4ab2e71e715c47fe1b152bce13fe20